Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Oligometastasis Metastatic Cancer Neoplasm Metastasis Neoplasms Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Duke Cancer Institute Cary, Cary, North Carolina, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years of age
Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
Patient must sign study-specific informed consent

Exclusion criteria

None

Treatment and study plan

Primary outcomes

Occurrence of acute adverse events following radiotherapy

Time frame: 90 Days

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trials Office

CONTACT

[email protected]

(919) 668 3726

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Important dates

Study start: 2019
Primary completion: 2029
Study completion: 2029
First posted: Sep 11, 2019
Registry last updated: Feb 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting